vs
Side-by-side financial comparison of Arteris, Inc. (AIP) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $20.1M, roughly 1.1× Arteris, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -42.2%, a 49.5% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 30.0%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 24.7%).
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
AIP vs CUE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.1M | $21.9M |
| Net Profit | $-8.5M | $1.6M |
| Gross Margin | 90.8% | — |
| Operating Margin | -42.0% | 9.0% |
| Net Margin | -42.2% | 7.2% |
| Revenue YoY | 30.0% | 1292.3% |
| Net Profit YoY | -3.7% | 116.7% |
| EPS (diluted) | $-0.19 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.1M | $21.9M | ||
| Q3 25 | $17.4M | $2.1M | ||
| Q2 25 | $16.5M | $3.0M | ||
| Q1 25 | $16.5M | $421.0K | ||
| Q4 24 | $15.5M | $1.6M | ||
| Q3 24 | $14.7M | $3.3M | ||
| Q2 24 | $14.6M | $2.7M | ||
| Q1 24 | $12.9M | $1.7M |
| Q4 25 | $-8.5M | $1.6M | ||
| Q3 25 | $-9.0M | $-7.4M | ||
| Q2 25 | $-9.1M | $-8.5M | ||
| Q1 25 | $-8.1M | $-12.3M | ||
| Q4 24 | $-8.2M | — | ||
| Q3 24 | $-7.7M | $-8.7M | ||
| Q2 24 | $-8.3M | $-10.2M | ||
| Q1 24 | $-9.4M | $-12.3M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 89.9% | — | ||
| Q2 25 | 89.4% | — | ||
| Q1 25 | 90.8% | — | ||
| Q4 24 | 89.8% | — | ||
| Q3 24 | 90.1% | — | ||
| Q2 24 | 90.0% | — | ||
| Q1 24 | 88.7% | — |
| Q4 25 | -42.0% | 9.0% | ||
| Q3 25 | -50.1% | -353.4% | ||
| Q2 25 | -50.0% | -292.3% | ||
| Q1 25 | -46.6% | -2921.4% | ||
| Q4 24 | -45.9% | — | ||
| Q3 24 | -53.8% | -264.2% | ||
| Q2 24 | -51.1% | -390.6% | ||
| Q1 24 | -70.5% | -737.8% |
| Q4 25 | -42.2% | 7.2% | ||
| Q3 25 | -51.6% | -346.6% | ||
| Q2 25 | -55.3% | -287.1% | ||
| Q1 25 | -49.1% | -2911.4% | ||
| Q4 24 | -53.0% | — | ||
| Q3 24 | -52.2% | -259.6% | ||
| Q2 24 | -57.2% | -382.7% | ||
| Q1 24 | -72.6% | -719.1% |
| Q4 25 | $-0.19 | $0.05 | ||
| Q3 25 | $-0.21 | $-0.07 | ||
| Q2 25 | $-0.22 | $-0.09 | ||
| Q1 25 | $-0.20 | $-0.17 | ||
| Q4 24 | $-0.19 | — | ||
| Q3 24 | $-0.20 | $-0.17 | ||
| Q2 24 | $-0.22 | $-0.20 | ||
| Q1 24 | $-0.25 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.9M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-14.6M | $26.4M |
| Total Assets | $115.0M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.9M | $27.1M | ||
| Q3 25 | $39.0M | $11.7M | ||
| Q2 25 | $38.0M | $27.5M | ||
| Q1 25 | $42.3M | $13.1M | ||
| Q4 24 | $43.8M | $22.5M | ||
| Q3 24 | $48.7M | $32.4M | ||
| Q2 24 | $45.8M | $30.0M | ||
| Q1 24 | $44.8M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $-14.6M | $26.4M | ||
| Q3 25 | $-11.4M | $13.2M | ||
| Q2 25 | $-7.5M | $18.2M | ||
| Q1 25 | $-4.8M | $6.6M | ||
| Q4 24 | $-1.2M | $17.5M | ||
| Q3 24 | $2.2M | $25.4M | ||
| Q2 24 | $5.3M | $21.6M | ||
| Q1 24 | $9.5M | $30.0M |
| Q4 25 | $115.0M | $42.2M | ||
| Q3 25 | $107.7M | $31.6M | ||
| Q2 25 | $106.9M | $40.7M | ||
| Q1 25 | $98.3M | $22.3M | ||
| Q4 24 | $106.1M | $32.2M | ||
| Q3 24 | $97.7M | $44.8M | ||
| Q2 24 | $96.4M | $42.3M | ||
| Q1 24 | $101.4M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $-1.1M |
| Free Cash FlowOCF − Capex | $3.0M | — |
| FCF MarginFCF / Revenue | 15.1% | — |
| Capex IntensityCapex / Revenue | 0.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | $5.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $-1.1M | ||
| Q3 25 | $3.2M | $-9.0M | ||
| Q2 25 | $-2.5M | $-3.4M | ||
| Q1 25 | $2.9M | $-8.2M | ||
| Q4 24 | $-2.6M | $-36.3M | ||
| Q3 24 | $1.1M | $-7.5M | ||
| Q2 24 | $311.0K | $-10.0M | ||
| Q1 24 | $477.0K | $-9.8M |
| Q4 25 | $3.0M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-2.8M | $-3.4M | ||
| Q1 25 | $2.7M | $-8.3M | ||
| Q4 24 | $-2.7M | $-36.4M | ||
| Q3 24 | $1.1M | $-7.5M | ||
| Q2 24 | $264.0K | $-10.0M | ||
| Q1 24 | $281.0K | $-9.8M |
| Q4 25 | 15.1% | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | -17.2% | -116.5% | ||
| Q1 25 | 16.2% | -1976.7% | ||
| Q4 24 | -17.3% | -2309.3% | ||
| Q3 24 | 7.4% | -225.7% | ||
| Q2 24 | 1.8% | -376.2% | ||
| Q1 24 | 2.2% | -573.0% |
| Q4 25 | 0.7% | 0.0% | ||
| Q3 25 | 4.1% | 0.0% | ||
| Q2 25 | 2.2% | 0.9% | ||
| Q1 25 | 1.1% | 35.6% | ||
| Q4 24 | 0.3% | 4.2% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.3% | 0.4% | ||
| Q1 24 | 1.5% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
